Johane M. Robitaille, MD; Roxanne M. Gillett, PhD; Marissa A. LeBlanc, PhD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1393-1399. doi:10.1001/jamaophthalmol.2014.2814
Robitaille et al identify gene mutations in patients who present with an familial exudative vitreoretinopathy (FEVR) phenotype and explore the spectrum of ocular and systemic abnormalities caused by KIF11 mutations in a cohort of patients with FEVR or microcephaly in conjunction with chorioretinopathy or FEVR.
Journal Club
Sharon L. Christ, PhD; D. Diane Zheng, MS; Bonnielin K. Swenor, PhD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1400-1406. doi:10.1001/jamaophthalmol.2014.2847
Christ et al evaluate the direct and indirect effects of change in visual acuity loss on mortality risk through functional status changes among aging adults.
Mi Jeung Kim, MD; Seok Hwan Kim, MD, PhD; Young Hoon Hwang, MD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1407-1413. doi:10.1001/jamaophthalmol.2014.2860
Kim and colleagues evaluate the diagnostic ability of a novel screening modality, the crescent moon sign (defined as the discontinuity between the superior or inferior optic rim margin and the temporal optic rim margin) for the detection of glaucomatous eyes with myopic tilted discs.
Shuai-Chun Lin, MD; Sophia Y. Wang, MD; Chungkwon Yoo, MD, PhD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1414-1420. doi:10.1001/jamaophthalmol.2014.2876
Lin and coauthors investigate the association between serum ferritin and glaucoma in the South Korean population.
Mikael Guedj, MD; Astrid Quéant, MD; Elisa Funck-Brentano, MD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1421-1425. doi:10.1001/jamaophthalmol.2014.3024
Guedj and coauthors assess the occurrence and severity of uveitis as an adverse effect of vemurafenib therapy
Jeannette Beckman Rehnman; Anders Behndig, MD, PhD; Per Hallberg, PhD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1426-1432. doi:10.1001/jamaophthalmol.2014.3029
Rehnman et al perform an in vivo study to quantify the biomechanical effects of corneal collagen crosslinking.
Stefano A. Gandolfi, MD; Nicola Ungaro, MD; Maria Grazia Tardini, AO; et al.
free access
JAMA Ophthalmol. 2014;132(12):1433-1438. doi:10.1001/jamaophthalmol.2014.3291
This randomized clinical trial suggests that drug-induced mydriasis can help in identifying eyes with pigment dispersion syndrome that are at risk for progressing to ocular hypertension. Nd:YAG laser peripheral iridotomy, when performed at the appropriate time and on high-risk eyes showing a concave iris root, can be protective over the long term.
Louis R. Pasquale, MD; Aliya Z. Jiwani, MD; Tzukit Zehavi-Dorin, MD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1439-1445. doi:10.1001/jamaophthalmol.2014.3326
This clinic-based case-control study conducted in the United States and Israel reports that lifetime outdoor activities, as related to geographic location and the extent of solar exposure, may contribute to exfoliation syndrome.
De-Kuang Hwang, MD, PhD; Catherine Jui-Ling Liu, MD; Cheng-Yun Pu, PhD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1446-1452. doi:10.1001/jamaophthalmol.2014.3333
This cohort study evaluates risk factors for nonpersistence among patients in Taiwan with open-angle glaucoma and ocular hypertension and suggests that factors other than cost, such as the physician-patient relationship and a patient’s education, may play an important role in the persistence of topical glaucoma medication.
Ronald B. Melles, MD; Michael F. Marmor, MD
free access
JAMA Ophthalmol. 2014;132(12):1453-1460. doi:10.1001/jamaophthalmol.2014.3459
This retrospective case-control study suggests that hydroxychloroquine retinopathy is more common than previously recognized, especially at high dosages and long duration of use.
-
Invited Commentary
We Need to Be Better Prepared for Hydroxychloroquine Retinopathy
Hendrik P. N. Scholl, MD, MA; Syed Mahmood Ali Shah, MBBS
JAMA Ophthalmol
Clinical Trial
Nienke Visser, MD; Henny J. M. Beckers, MD, PhD; Noel J. C. Bauer, MD, PHD; et al.
free access
JAMA Ophthalmol. 2014;132(12):1462-1468. doi:10.1001/jamaophthalmol.2014.3602
This randomized clinical trial identifies higher spectacle independency with bilateral toric intraocular lens implantation but no significant changes in other outcomes.